Physician profile
Joanna A Davis
NPI 1306873864
$411,182.12
in general payments reported to CMS, 2019-2025
15 companies · $13K in 2025
The $13K reported for 2025 was more than what 88% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $50K · 2021: $61K · 2022: $45K · 2023: $87K · 2024: $60K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $24K · Travel and Lodging: $17K · Honoraria: $3,000 · Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,316.50 |
| Consulting Fee | $24,009.50 |
| Travel and Lodging | $16,832.41 |
| Honoraria | $3,000.00 |
| Food and Beverage | $1,842.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $185,206.21 | 2020-2025 | |
| Genentech USA, INC. | $80,672.33 | 2019-2024 | Hemlibra |
| Spark Therapeutics, INC. | $57,172.24 | 2019-2023 | |
| Csl Behring | $22,660.94 | 2019-2021 | |
| Novo Nordisk INC | $19,715.16 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $14,335.00 | 2020-2022 | |
| Shire North American Group INC | $11,158.18 | 2019 | |
| Pfizer INC. | $5,175.29 | 2020-2024 | |
| Octapharma USA, INC. | $5,075.50 | 2021-2024 | Nuwiq |
| Sanofi-Aventis U.S. LLC | $3,071.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,900.00 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,375.00 | 2020 | |
| Bioverativ Therapeutics INC. | $1,592.50 | 2021 | |
| Genentech, INC. | $47.95 | 2020 | |
| Convatec INC. | $24.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.